Skip to main content
Fig. 2 | BMC Complementary Medicine and Therapies

Fig. 2

From: Amygdalin-folic acid-nanoparticles inhibit the proliferation of breast cancer and enhance the effect of radiotherapy through the modulation of tumor-promoting factors/ immunosuppressive modulators in vitro

Fig. 2

Cytotoxicity and inhibition of BC cells proliferation, in vitro release, enhanced selectivity, and cellular uptake of Amy-F nanoparticles. a MTT assay of BC and MCF-10A cells treated with Amy-F at different concentrations; b Representative phase-contrast images of MCF-10A, MCF-7, and MDA-MB-231 cells captured by the inverted light microscope; c The release of Amy-F at different pH; 6, 7, and 9 dispersed in PBS containing DMSO 0.1% estimated using UV–vis spectrometry; d Representative histogram of the FR-α expression in normal (MCF-10A) and BC cells; e Intracellular FA uptake values in MCF-10A, MCF-7, and MDA-MB-231 cells after 24 h incubation with Amy-F at IC50 doses. Values are represented as the mean ± standard error of the mean (SEM) of triplicate samples from two independent experiments. Values at a1p < 0.001, a2p < 0.01 vs untreated normal cells; b1p < 0.001, b2p < 0.01 vs. untreated cancer cells are considered significant

Back to article page